We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HealthEquity (HQY) Q1 Earnings and Revenues Beat Estimates
Read MoreHide Full Article
HealthEquity Inc (HQY - Free Report) reported earnings of 19 cents per share in the first quarter of fiscal 2018, higher than the Zacks Consensus Estimate of 16 cents. The figure was higher than the year-ago earnings of 14 cents on revenue and margin expansion.
Stock Performance
The price performance of the stock has been favorable over the last three months. HealthEquity rose 11.19%, while the Zacks classified Medical Services sub-industry declined almost 3.01%.
HealthEquity, Inc. Price, Consensus and EPS Surprise
Revenues came in at $55.4 million, reflecting an increase of 26% year over year and also surpassed the Zacks Consensus Estimate of $55.0 million. Service (41% of total revenues), Custodial (35%) and Interchange (24%) revenues were up 18%, 40% and 21% year over year, respectively.
The growth in service revenues were driven by year-over-year increase in average health savings account (HSA) which was offset by a decrease in service revenue per average HSA. The decline was led by the company’s strategy of offering lower service fees per HSA for more volume from network partners, particularly with higher balances. HealthEquity stated that the profitability of an HSA in this business model increases as balances grow.
The growth in Custodial revenues was supported by higher average daily cash AUM. The strong year-over-year growth in Interchange revenues was driven by increased card spending and more favorable interchange terms (higher spend volume).
As of Apr 30, 2017, total number of HSA members – for which the company serves as a non-bank custodian – increased 26% year over year to 2.8 million. Total assets under management (AUM) surged 28% year over year to $5.2 billion.
Financial Condition
As of Apr 30, 2017, the company had $195.6 million of cash, cash equivalents and marketable securities without any outstanding debt. This compares favorably with $180.4 million in cash, cash equivalents and marketable securities and no outstanding debt as of Jan 31, 2017.
Guidance
For fiscal 2018 (ending Jan 31, 2018), HealthEquity forecasts revenues in the range of $222–$227 million. Net income is forecasted in the range of $33.0 million to $37.0 million, resulting in a net income per diluted share range of 62 cents to 67 cents. Adjusted EBITDA outlook is estimated in the band of $78.0 million to $83.0 million. The business outlook for the fiscal ending Jan 31, 2018 assumes a projected effective income tax rate of approximately 38%.
Zacks Rank and Key Picks
Currently, HealthEquity has a Zacks Rank #3 (Hold).
Align Technology has an expected long-term adjusted earnings growth of almost 22.8%. The stock roughly added 45.7% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has solid one-year return of around 79.7%.
Accelerate Diagnostics has expected long-term adjusted earnings growth of 30%. The stock has added 14% roughly over last three months.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HealthEquity (HQY) Q1 Earnings and Revenues Beat Estimates
HealthEquity Inc (HQY - Free Report) reported earnings of 19 cents per share in the first quarter of fiscal 2018, higher than the Zacks Consensus Estimate of 16 cents. The figure was higher than the year-ago earnings of 14 cents on revenue and margin expansion.
Stock Performance
The price performance of the stock has been favorable over the last three months. HealthEquity rose 11.19%, while the Zacks classified Medical Services sub-industry declined almost 3.01%.
HealthEquity, Inc. Price, Consensus and EPS Surprise
HealthEquity, Inc. Price, Consensus and EPS Surprise | HealthEquity, Inc. Quote
Quarter Details
Revenues came in at $55.4 million, reflecting an increase of 26% year over year and also surpassed the Zacks Consensus Estimate of $55.0 million. Service (41% of total revenues), Custodial (35%) and Interchange (24%) revenues were up 18%, 40% and 21% year over year, respectively.
The growth in service revenues were driven by year-over-year increase in average health savings account (HSA) which was offset by a decrease in service revenue per average HSA. The decline was led by the company’s strategy of offering lower service fees per HSA for more volume from network partners, particularly with higher balances. HealthEquity stated that the profitability of an HSA in this business model increases as balances grow.
The growth in Custodial revenues was supported by higher average daily cash AUM. The strong year-over-year growth in Interchange revenues was driven by increased card spending and more favorable interchange terms (higher spend volume).
As of Apr 30, 2017, total number of HSA members – for which the company serves as a non-bank custodian – increased 26% year over year to 2.8 million. Total assets under management (AUM) surged 28% year over year to $5.2 billion.
Financial Condition
As of Apr 30, 2017, the company had $195.6 million of cash, cash equivalents and marketable securities without any outstanding debt. This compares favorably with $180.4 million in cash, cash equivalents and marketable securities and no outstanding debt as of Jan 31, 2017.
Guidance
For fiscal 2018 (ending Jan 31, 2018), HealthEquity forecasts revenues in the range of $222–$227 million. Net income is forecasted in the range of $33.0 million to $37.0 million, resulting in a net income per diluted share range of 62 cents to 67 cents. Adjusted EBITDA outlook is estimated in the band of $78.0 million to $83.0 million. The business outlook for the fiscal ending Jan 31, 2018 assumes a projected effective income tax rate of approximately 38%.
Zacks Rank and Key Picks
Currently, HealthEquity has a Zacks Rank #3 (Hold).
Few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Align Technology and Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 22.8%. The stock roughly added 45.7% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has solid one-year return of around 79.7%.
Accelerate Diagnostics has expected long-term adjusted earnings growth of 30%. The stock has added 14% roughly over last three months.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>